Intellipharmaceutics International Stock Net Asset
Intellipharmaceutics International fundamentals help investors to digest information that contributes to Intellipharmaceutics' financial success or failures. It also enables traders to predict the movement of Intellipharmaceutics OTC Stock. The fundamental analysis module provides a way to measure Intellipharmaceutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Intellipharmaceutics otc stock.
Intellipharmaceutics |
Intellipharmaceutics International OTC Stock Net Asset Analysis
Intellipharmaceutics' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Intellipharmaceutics Net Asset | 2.1 M |
Most of Intellipharmaceutics' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intellipharmaceutics International is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
CompetitionBased on the recorded statements, Intellipharmaceutics International has a Net Asset of 2.1 M. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Intellipharmaceutics Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intellipharmaceutics' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Intellipharmaceutics could also be used in its relative valuation, which is a method of valuing Intellipharmaceutics by comparing valuation metrics of similar companies.Intellipharmaceutics is currently under evaluation in net asset category among its peers.
Intellipharmaceutics Fundamentals
| Return On Asset | -0.98 | |||
| Operating Margin | (106.06) % | |||
| Current Valuation | 4.47 M | |||
| Shares Outstanding | 33.09 M | |||
| Shares Owned By Insiders | 1.70 % | |||
| Shares Owned By Institutions | 11.09 % | |||
| Number Of Shares Shorted | 714 K | |||
| Price To Earning | (0.50) X | |||
| Price To Sales | 66.19 X | |||
| Gross Profit | 1.4 M | |||
| EBITDA | (4.45 M) | |||
| Net Income | (5.15 M) | |||
| Cash And Equivalents | 79.65 K | |||
| Total Debt | 2.01 M | |||
| Debt To Equity | 165.20 % | |||
| Current Ratio | 0.05 X | |||
| Book Value Per Share | (0.31) X | |||
| Cash Flow From Operations | (2.46 M) | |||
| Short Ratio | 0.39 X | |||
| Earnings Per Share | (0.16) X | |||
| Target Price | 25.0 | |||
| Number Of Employees | 11 | |||
| Beta | 1.0 | |||
| Market Capitalization | 2.02 M | |||
| Total Asset | 2.1 M | |||
| Retained Earnings | (86.55 M) | |||
| Working Capital | (5.62 M) | |||
| Current Asset | 1.41 M | |||
| Current Liabilities | 7.02 M | |||
| Z Score | -65.8 | |||
| Net Asset | 2.1 M |
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Consideration for investing in Intellipharmaceutics OTC Stock
If you are still planning to invest in Intellipharmaceutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intellipharmaceutics' history and understand the potential risks before investing.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |